| Not Yet Recruiting | A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma T-cell NHL (PTCL or CTCL) | Phase 1 | 2026-01-23 |
| Active Not Recruiting | Mogamulizumab Q4week Dosing in Participants With R/R CTCL Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory | Phase 2 | 2021-08-16 |
| Completed | Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches. Healthy Volunteers | Phase 1 | 2021-07-06 |
| Completed | Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite Hepatic Impairment | Phase 1 | 2019-11-26 |
| Terminated | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer Urothelial Carcinoma | Phase 1 | 2019-09-26 |
| Recruiting | Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL | — | 2019-09-10 |
| Completed | Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356 Healthy Male Subjects | Phase 1 | 2019-08-21 |
| Completed | Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2018-10-22 |
| Completed | Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients Wi X-Linked Hypophosphatemia | Phase 3 | 2016-09-08 |
| Completed | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumo Solid Tumor, Cancer, Carcinoma | Phase 1 | 2016-08-01 |
| Completed | Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative | Phase 2 | 2016-06-01 |
| Completed | Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-link X-Linked Hypophosphatemia | Phase 2 | 2016-05-05 |
| Completed | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors Solid Tumor, Cancer, Carcinoma | Phase 1 / Phase 2 | 2016-02-01 |
| Completed | Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) X-linked Hypophosphatemia | Phase 3 | 2015-12-23 |
| Completed | Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) X-linked Hypophosphatemia | Phase 3 | 2015-10-22 |
| Completed | Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS) | Phase 2 | 2015-03-24 |
| Completed | Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) X-Linked Hypophosphatemia | Phase 2 | 2015-01-30 |
| Completed | Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer Non-Small Cell Lung Cancer | Phase 1 | 2015-01-01 |
| Completed | Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Advanced Solid Tumors | Phase 1 | 2014-11-26 |
| Completed | Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 X-linked Hypophosphatemia | Phase 2 | 2014-07-02 |
| Terminated | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | 2014-06-01 |
| Completed | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Cutaneous T-Cell Lymphoma | Phase 3 | 2012-11-01 |
| Completed | KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Adult T-cell Leukemia-Lymphoma | Phase 2 | 2012-06-01 |
| Completed | Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer Colorectal Cancer | Phase 1 | 2007-06-01 |
| Terminated | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leuk Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes | Phase 1 | 2006-06-01 |
| Terminated | An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-IN Parkinson's Disease | Phase 3 | 2005-10-01 |
| Completed | Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome Sleep Disorder, Restless Legs Syndrome | Phase 2 | 2005-07-01 |
| Completed | A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients Parkinson's Disease, Movement Disorder Syndrome | Phase 2 | 2005-05-01 |
| Terminated | A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma Stage IV Melanoma | Phase 1 / Phase 2 | 2004-11-01 |
| Completed | An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US Parkinson's Disease | Phase 3 | 2004-10-01 |
| Completed | A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa Parkinson's Disease | Phase 3 | 2004-07-01 |
| Completed | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa Parkinson's Disease | Phase 3 | 2004-06-01 |
| Completed | A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications Parkinson's Disease | Phase 2 / Phase 3 | 2002-08-01 |
| Completed | 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson' Parkinson's Disease | Phase 2 | 2002-04-01 |
| Completed | 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Pati Parkinson's Disease | Phase 2 | 2002-03-01 |
| No Longer Available | Expanded Access for KHK2455 Glioblastoma Multiforme | — | — |